Viatris Signs Exclusive Licensing Deal with Lexicon for Sotagliflozin Outside U.S. and Europe PITTSBURGH, Oct. 16, 2024 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS) has reached an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) to market sotagliflozin in all…
Alnylam Submits Type II Variation to EMA for Vutrisiran in ATTR Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 16, 2024—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced the submission of a Type II Variation to the European Medicines Agency (EMA) for vutrisiran, an…
Sanofi and Orano Partner to Develop Next-Generation Radioligand Therapies Paris, October 17, 2024 – Sanofi and Orano Med, a subsidiary of the Orano Group and a leader in targeted alpha therapies for oncology, have announced a partnership to combine their…
AstraZeneca Showcases Key Advances in Respiratory Infection Protection at IDWeek 2024 AstraZeneca is set to present significant new findings on the protection against serious respiratory infections caused by respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and COVID-19 at IDWeek 2024,…
ViiV Healthcare Presents Real-World Evidence for Apretude (Cabotegravir Long-Acting) at IDWeek 2024 GSK plc (LSE/NYSE: GSK) has announced that ViiV Healthcare, a global leader in HIV treatment and prevention, has shared new real-world evidence on the effectiveness, adherence, and quality-of-life…
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024 GenSight Biologics (Euronext: SIGHT), a biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced new scientific data on its gene therapy, LUMEVOQ®,…
Exscientia Reaches Key Milestones in Two Programs Under Sanofi Collaboration Exscientia has achieved significant progress in two discovery programs under its collaboration with Sanofi, earning $15 million in milestone payments. These programs have advanced to the core optimization phase, meeting…
Grifols Achieves Record Score in 2024 S&P Global Corporate Sustainability Assessment Grifols Secures 70 Points, Demonstrating a Seven-Point Improvement Over Previous Year Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global healthcare company and manufacturer of plasma-derived medicines, has…
Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to felzartamab, an investigational anti-CD38 monoclonal antibody. This designation is for the treatment of late antibody-mediated rejection (AMR)…
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Itovebi™ (inavolisib) for use in combination with palbociclib (Ibrance®) and fulvestrant to treat adults with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor…
Gilead Sciences, Inc. (Nasdaq: GILD) has announced the signing of non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to produce and distribute generic lenacapavir in 120 high-incidence, resource-limited countries, primarily targeting low- and lower-middle-income regions. These agreements precede any…